Primary Targets of Fluoroquinolones in Streptococcus pneumoniae | Zendy

Hideyuki Fukuda | Zendy; Keiichi Hiramatsu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Primary Targets of Fluoroquinolones in Streptococcus pneumoniae

Author(s) -

Hideyuki Fukuda,

Keiichi Hiramatsu

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.2.410

Subject(s) - sparfloxacin , gatifloxacin , norfloxacin , trovafloxacin , dna gyrase , levofloxacin , microbiology and biotechnology , streptococcus pneumoniae , topoisomerase iv , ciprofloxacin , ofloxacin , antibacterial agent , ertapenem , biology , antibiotics , antibiotic resistance , escherichia coli , genetics , imipenem , gene

Mutants of wild-type Streptococcus pneumoniae IID553 with mutations in parC were obtained by selection with trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin. All of the parC mutants were cross-resistant to the selecting agents but were not resistant to gatifloxacin and sparfloxacin. On the other hand, gyrA mutants were isolated by selection with gatifloxacin and sparfloxacin. The gyrA mutants were cross-resistant to gatifloxacin and sparfloxacin but were not resistant to the other fluoroquinolones tested. These results suggest that in wild-type S. pneumoniae the primary target of trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin is topoisomerase IV, whereas the primary target of gatifloxacin and sparfloxacin is DNA gyrase.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research